Edwards Lifesciences Corporation (EW) | Rumor.io

Edwards Lifesciences

Attention (50-day avg)0%

Attention rank (50-day avg)#3,685

Bullish sentiment (50-day avg)100%

Price to earnings ratio51.4

Market capitalization50B

Earnings per share1.68

Dividend yield (TTM)—

Revenue (annual)6.1B

Net income (annual)1.1B

Social

What share of all stock conversation is about EW?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 19

Edwards Lifesciences Corporation (EW) announced a 3% revenue increase in Q4.
The company reported a 4% increase in its global sales of heart valves in the same period.
Edwards Lifesciences expects a 5-7% revenue growth in 2023.

Generated by AI

Sentiment

Of the messages about EW that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.24% +5.69
Bearish	—	—	—	0.76% -5.69

Bullish· Jul 25

Edwards Lifesciences Corporation is considered a good buy due to its long-term potential and recent acquisition.
The company's recent drop is seen as excessive and a potential long-term bargain, with some expecting a rebound in the next couple of weeks.
The stock is considered oversold and may be due for a bounce, with some targets set at $70 or higher, and a potential move to $90 in the near future.

Bearish· Jul 26

Edwards Lifesciences (EW) has a history of poor performance, with a 300% increase from 2014 to 2019 followed by a mere 1% gain from 2019 to 2024.
The company's stock has been significantly overvalued, with analysts cutting their target prices by as much as 34% in a single day.
Edwards Lifesciences' recent earnings report was its worst in 9 years, with a 29% single-session stock price drop wiping out $13 billion in value.

Generated by AI

Topics

Of the messages about EW that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	11.28%
Technical Analysis	—	—	—	3.21%
Analysts	—	—	—	44.49%
Macro	—	—	—	39.54%
Earnings	—	—	—	1.15%
Controversies	—	—	—	0.34%

Earnings· Jul 28

Edwards Lifesciences ($EW) reported Q2 earnings of $0.63 EPS and $1.37B revenue, missing estimates by $0.01 EPS and $30M revenue.
The company guided Q3 EPS in-line but Q3 revenue below consensus, and slashed FY22 sales outlook.
Edwards Lifesciences shares slid as Q2 results missed expectations, with underlying sales growing 5% and TAVR sales growing 1%.

Analysts· Oct 28

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences ($EW) with an Outperform rating and lowers the price target from $128 to $118.
Piper Sandler analyst Adam Maeder lowers Edwards Lifesciences ($EW) price target to $95.00 with an Overweight rating.
Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences ($EW) with an Overweight rating and lowers the price target from $121 to $93.

Announcements· Oct 30

Edwards Lifesciences Corporation (EW) has been mentioned in several breaking news posts regarding Ebay's (EBAY) trading advice, but no specific announcements or updates about the company have been made.
There is no mention of Edwards Lifesciences Corporation making any announcements or updates, and its ticker is only mentioned in the context of other companies' news.
The company's focus is not on Edwards Lifesciences Corporation, but rather on other companies, with no specific market-relevant information about Edwards Lifesciences Corporation being shared.

Controversies· May 20

Medtronic ($MDT) has agreed to pay $750 million and quarterly royalties until April 2022 to settle a patent dispute with Edwards Lifesciences ($EW) regarding transcatheter heart valves.
The settlement is estimated to be over $1 billion, with Medtronic paying a one-time fee and quarterly royalties to Edwards Lifesciences.
The dispute between Medtronic and Edwards Lifesciences has been ongoing, with Edwards Lifesciences emerging as the winner in the patent settlement, but potentially losing in the market.

Technical Analysis· Oct 26

$EW potential bottom channel hit, with importance placed on its handling of the current price.
RSI of 16.89 for $EW is considered oversold, with a previous low seen only on $DDD's chart.
$EW has potential for a rebound over 96, with a possible test of 89.50 if it doesn't bounce.

Generated by AI

Community

Of the messages about EW, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	29.78%
Newcomers	100%	100%	100%	70.22%

Regulars· Oct 25

Edwards Lifesciences' stock price is down -7.48% after hours, a significant decline.
The Edwards Sapien 3 Valve has shown excellent survival rates in five-year data from the Partner 3 trial.
Edwards Lifesciences' quarterly sales have jumped due to robust demand for heart devices, with revenue reaching $1.48B.

Newcomers· Nov 11

New users are concerned about the potential for market saturation in the TAVR (Transcatheter Aortic Valve Replacement) market, which could negatively impact Edwards Lifesciences Corporation (EW).
Some newcomers are focused on the bearish pressure that market saturation could exert on Edwards Lifesciences Corporation (EW), citing a current price of $90.20.
The new users are primarily discussing the impact of market saturation on Edwards Lifesciences Corporation (EW), rather than the broader market or general economic conditions.

Generated by AI

Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...

11d agofinance.yahoo.com

Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion

Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...

11d agofinance.yahoo.com

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors

12d agoMarketWatch

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

13d agoMarketWatch

Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth

13d agoInvesting.com

Also Discussed

Investors talking about EW also mention

#	Name	Attention
1	Boston Scientific Corp.BSX	0.03%-0.02
2	ABMD - Abiomed, Inc.	——
3	Stryker CorporationSYK	0.01%+0.01
4	Medtronic plcMDT	0%+0
5	CSII - Cardiovascular Systems, Inc.	——
6	DexCom Inc.DXCM	0%0
7	Intuitive Surgical Inc.ISRG	0%0
8	iShares U.S. Medical Devices ETFIHI	0%-0.02
9	Alico Inc.ALCO	0%0
10	Procore Technologies Inc.PCOR	0%new

Edwards Lifesciences Corporation

Healthcare
Medical Devices

Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.

Website

Location

One Edwards Way

Irvine, CA, 92614

United States

Social

What share of all stock conversation is about EW?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

May 19

Edwards Lifesciences Corporation (EW) announced a 3% revenue increase in Q4.
The company reported a 4% increase in its global sales of heart valves in the same period.
Edwards Lifesciences expects a 5-7% revenue growth in 2023.

Generated by AI

Sentiment

Of the messages about EW that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.24% +5.69
Bearish	—	—	—	0.76% -5.69

Bullish· Jul 25

Edwards Lifesciences Corporation is considered a good buy due to its long-term potential and recent acquisition.
The company's recent drop is seen as excessive and a potential long-term bargain, with some expecting a rebound in the next couple of weeks.
The stock is considered oversold and may be due for a bounce, with some targets set at $70 or higher, and a potential move to $90 in the near future.

Bearish· Jul 26

Edwards Lifesciences (EW) has a history of poor performance, with a 300% increase from 2014 to 2019 followed by a mere 1% gain from 2019 to 2024.
The company's stock has been significantly overvalued, with analysts cutting their target prices by as much as 34% in a single day.
Edwards Lifesciences' recent earnings report was its worst in 9 years, with a 29% single-session stock price drop wiping out $13 billion in value.

Generated by AI

Topics

Of the messages about EW that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	11.28%
Technical Analysis	—	—	—	3.21%
Analysts	—	—	—	44.49%
Macro	—	—	—	39.54%
Earnings	—	—	—	1.15%
Controversies	—	—	—	0.34%

Earnings· Jul 28

Edwards Lifesciences ($EW) reported Q2 earnings of $0.63 EPS and $1.37B revenue, missing estimates by $0.01 EPS and $30M revenue.
The company guided Q3 EPS in-line but Q3 revenue below consensus, and slashed FY22 sales outlook.
Edwards Lifesciences shares slid as Q2 results missed expectations, with underlying sales growing 5% and TAVR sales growing 1%.

Analysts· Oct 28

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences ($EW) with an Outperform rating and lowers the price target from $128 to $118.
Piper Sandler analyst Adam Maeder lowers Edwards Lifesciences ($EW) price target to $95.00 with an Overweight rating.
Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences ($EW) with an Overweight rating and lowers the price target from $121 to $93.

Announcements· Oct 30

Edwards Lifesciences Corporation (EW) has been mentioned in several breaking news posts regarding Ebay's (EBAY) trading advice, but no specific announcements or updates about the company have been made.
There is no mention of Edwards Lifesciences Corporation making any announcements or updates, and its ticker is only mentioned in the context of other companies' news.
The company's focus is not on Edwards Lifesciences Corporation, but rather on other companies, with no specific market-relevant information about Edwards Lifesciences Corporation being shared.

Controversies· May 20

Medtronic ($MDT) has agreed to pay $750 million and quarterly royalties until April 2022 to settle a patent dispute with Edwards Lifesciences ($EW) regarding transcatheter heart valves.
The settlement is estimated to be over $1 billion, with Medtronic paying a one-time fee and quarterly royalties to Edwards Lifesciences.
The dispute between Medtronic and Edwards Lifesciences has been ongoing, with Edwards Lifesciences emerging as the winner in the patent settlement, but potentially losing in the market.

Technical Analysis· Oct 26

$EW potential bottom channel hit, with importance placed on its handling of the current price.
RSI of 16.89 for $EW is considered oversold, with a previous low seen only on $DDD's chart.
$EW has potential for a rebound over 96, with a possible test of 89.50 if it doesn't bounce.

Generated by AI

Community

Of the messages about EW, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	29.78%
Newcomers	100%	100%	100%	70.22%

Regulars· Oct 25

Edwards Lifesciences' stock price is down -7.48% after hours, a significant decline.
The Edwards Sapien 3 Valve has shown excellent survival rates in five-year data from the Partner 3 trial.
Edwards Lifesciences' quarterly sales have jumped due to robust demand for heart devices, with revenue reaching $1.48B.

Newcomers· Nov 11

New users are concerned about the potential for market saturation in the TAVR (Transcatheter Aortic Valve Replacement) market, which could negatively impact Edwards Lifesciences Corporation (EW).
Some newcomers are focused on the bearish pressure that market saturation could exert on Edwards Lifesciences Corporation (EW), citing a current price of $90.20.
The new users are primarily discussing the impact of market saturation on Edwards Lifesciences Corporation (EW), rather than the broader market or general economic conditions.

Generated by AI

Edwards Lifesciences

Social

May 19

Bullish· Jul 25

Bearish· Jul 26

Earnings· Jul 28

Analysts· Oct 28

Announcements· Oct 30

Controversies· May 20

Technical Analysis· Oct 26

Regulars· Oct 25

Newcomers· Nov 11

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions

Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth

Also Discussed

Edwards Lifesciences Corporation

Company Information

Location

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions

Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

Edwards Lifesciences at deutsche bank 2026 healthcare summit: broader growth

Also Discussed

Social

May 19

Bullish· Jul 25

Bearish· Jul 26

Earnings· Jul 28

Analysts· Oct 28

Announcements· Oct 30

Controversies· May 20

Technical Analysis· Oct 26

Regulars· Oct 25

Newcomers· Nov 11